34 results about "Multidrug resistant bacteria" patented technology

The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms and fungi, and is proved to be very efficient for the inhibition of particularly vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can be used as an excellent antibiotic against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA), and thus the present invention is a very useful invention for medical industry.

Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza / amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.

Disclosed is a novel antimicrobial agent for Gram-positive bacteria extending beyond the mechanism of bacterial drug resistance. The antimicrobial agent contains, as active ingredients, particles which adhere to a Gram-positive bacterial cell wall and do not adhere to a mammalian cell membrane, have a particle diameter of 5 [mu]m or less, and practically do not contain an antimicrobially active component against Gram-positive bacteria. According to the antimicrobial agent of the invention, antimicrobial effect also on Gram-positive bacteria showing multidrug resistance typified by MRSA and VRE can be achieved. Further, the emergence of new multidrug resistant bacteria which becomes a major problem in the use of an antibiotic can be avoided.

The invention relates to the field of medicinal chemistry, and particularly relates to a five-membered heterocyclic dicarbonyl derivative (I) and applications thereof for resisting multidrug-resistant bacteria. Proved by pharmacological tests, the compound is jointly combined with antibiotics, thus having better inhibition effect on the multidrug-resistant bacteria.

A pleuromutilin derivative having a 2-amino phenyl mercaptan side chain as well as a preparation method and application thereof are provided. The derivative has a structure represented by formula 2 or formula 3, wherein, R1, R2 and R3 are each independently selected from a hydrogen atom, hydroxyl, amino, sulfydryl, hydroxymethyl, amine methyl, nitro, halogen, trihalogenated methyl, methyl, natural amino acid acylamino and C1-6 alkoxy. The plueuromutilin derivative in the disclosure has good activity of inhibiting drug-resistant Staphylococcus aureus and mycoplasma, and is especially suitable for preventing and treating infectious diseases caused by human or animal mycoplasma or drug-resistant Staphylococcus aureus or multidrug resistant bacteria as a novel antibacterial drug.

The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

Disclosed are a benzoxazine oxazolidinone compound shown by a general formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an application thereof in preparing a drug for treating an infectious disease and in particular, an infectious disease caused by multidrug resistant bacteria.

To provide a multidrug-resistant Gram positive bacteria antibacterial agent containing as an active ingredient a novel component to which multidrug-resistant bacteria are not resistant, and an external agent containing the same. The multidrug resistant Gram-positive bacteria antibacterial agent according to the present invention contains an amphipathic compound having an HLB value of greater than 9.5 and 20 or less and an acyl group as an active ingredient. The external agent according to the present invention contains the multidrug resistant Gram-positive bacteria antibacterial agent.

The invention belongs to the technical field of preparation of nano-selenium, and discloses functional nano-selenium and preparation method thereof as well as application of functional nano-selenium in preparation of anti-bacteria and sterilization drugs. The functional nano-selenium is at least one of nano-selenium modified by quercetin, nano-selenium modified by acetylcholine chloride and nano-selenium modified by quercetin-acetylcholine chloride. The functional nano-selenium has the activity for killing bacteria and multidrug resistant bacteria, also has the biological activity for inhibiting the growth of bacteria and multidrug resistant bacteria, and is suitable for preparing drugs for inhibiting the growth of bacteria and multidrug resistant bacteria and sterilization drugs. The functional nano-selenium is simple in preparation method, can be obtained through in-situ reduction modification, and can be directly stored and used. The functional nano-selenium is modified through various functions, so that the targeting property of the functional nano-selenium is improved, the transportation and transmembrane absorption of the functional nano-selenium in a bacteria cell membrane are improved, the medicine intake of bacteria can be increased, and the discharge is reduced, so that the fact that drugs in bacteria cells are kept at a higher level is ensured.